Photo Rounds

Dark toenail line

A 28-year-old woman with no personal or family history of skin cancer presented to the Family Medicine Skin Clinic with a dark line on her left great toenail of 10 years’ duration. None of her other nails were affected and she had no other symptoms.

What is your diagnosis?


 

References

Dark toenail line

This woman’s linear hyperpigmentation is formally known as longitudinal melanonychia.

After the initial diagnosis, it is important to determine if the melanonychia is due to melanoma or a benign process. Many people with darker skin types (Fitzpatrick skin types V or VI) have several of these lines, so it is reassuring when these lines are present on multiple digits. Additional evaluation is warranted, however, when only 1 longitudinal melanonychia is present.

In this case, it was clear that the pigmentation was homogeneous and in a parallel line format. (Dermoscopy can aid in the evaluation of such lesions.) There was no spreading of the pigmentation onto the skin around the nail (Hutchinson sign), which would be suggestive of melanoma. The patient noted that the lesion had been present (without progression) over a 10-year period, which also was consistent with a benign process. A new lesion, rapid change, a triangular pattern wider at the cuticle vs the distal nail, and nail disruption are worrisome features that would have warranted a biopsy.

If a biopsy is called for, be sure to sample the origin of the pigmentation under the cuticle and the nail at the nail matrix. This requires partial or complete nail removal to reach the matrix, and there is a risk of permanent nail disruption. In light of this, it’s important to discriminate which lesions are at higher risk for melanoma.

In this patient, who had a stable lesion and no concerning history or findings, it was likely that she had a benign nevus or lentigo in the nail matrix. She was instructed to watch for any changes and to notify her physician if any occurred, as such changes might require a biopsy.

Photo and text courtesy of Daniel Stulberg, MD, FAAFP, Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque.

Recommended Reading

FDA approves ixekizumab for pediatric plaque psoriasis
MDedge Family Medicine
Low-income DC communities have restricted access to iPLEDGE pharmacies
MDedge Family Medicine
Thickening of tattoo
MDedge Family Medicine
Routinely screen for depression in atopic dermatitis
MDedge Family Medicine
iPLEDGE allows at-home pregnancy tests during pandemic
MDedge Family Medicine
Novel acne drug now under review at the FDA
MDedge Family Medicine
A decade of telemedicine policy has advanced in just 2 weeks
MDedge Family Medicine
Red painful nodules in a hospitalized patient
MDedge Family Medicine
D.C.-area blacks face increased risk of mortality from SJS/TEN
MDedge Family Medicine
Dupilumab hits the mark for severe AD in younger children
MDedge Family Medicine